Back to results
US 2003/0125261 A1Published application
Penta- and hexapeptides having antiangiogenic activity
OwnerFortuna Haviv, Michael F. Bradleyinventors
Life of this patent
Estimating the term…
Abstract
Compounds of formula (SEQ ID NO:1), which are useful for treating conditions that arise from or are exacerbated by angiogenesis, are described. Also disclosed are pharmaceutical compositions comprising these compounds, methods of treatment using these compounds, and methods of inhibiting angiogenesis.
Claims17
A compound of formula (I)
- Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7 (I), (SEQ ID NO:
- 1);
- or a therapeutically acceptable salt thereof, wherein
- Xaa1 is absent or R-(CH2)n—C(O)—, wherein n is an integer from 0 to 8 and R is selected from the group consisting of alkoxy, alkyl, amino, aryl, carboxyl, cycloalkenyl, cycloalkyl, and heterocycle;
- Xaa2 is selected from the group consisting of allothreonyl, allylglycyl, aspartyl, glutaminyl, D-glutaminyl, N-methylglutamyl, glycyl, homoseryl, histidyl, isoleucyl, lysyl(N-epsilon-acetyl), methionyl, seryl, N-methylseryl, threonyl, D-threonyl, tryptyl, tyrosyl, and tyrosyl(O-methyl);
- Xaa3 is selected from the group consisting of N-methylalanyl, allothreonyl, arginyl, glutaminyl, D-glutaminyl, glycyl, homoseryl, leucyl, lysyl(N-epsilon-acetyl), norleucyl, norvalyl, D-norvalyl, N-methylnorvalyl, omithyl(N-delta-acetyl), 3-(3-pyridyl)alanyl, sarcosyl, seryl, N-methylseryl, threonyl, tryptyl, valyl, and N-methylvalyl;
- Xaa4 is selected from the group consisting of alanyl, alloisoleucyl, aspartyl, citrullyl, isoleucyl, D-isoleucyl, N-methylisoleucyl, leucyl, D-leucyl, lysyl, lysyl(N-epsilon-acetyl), D-lysyl(N-epsilon-acetyl), norvalyl, phenylalanyl, prolyl, and D-prolyl;
- Xaa5 is selected from the group consisting of arginyl, D-arginyl, citrullyl, histidyl, lysyl, lysyl(N-epsilon-isopropyl), omithyl, and 3-(3-pyridyl)alanyl;
- Xaa6 is selected from the group consisting of N-methyl-D-alanyl, 2-aminobutyryl, 2-aminoisobutyryl, D-glutaminyl, homoprolyl, hydroxyprolyl, leucyl, phenylalanyl, prolyl, D-prolyl, and D-valyl;
- and
- Xaa7 is selected from the group consisting of D-alanylamide, azaglycylamide, glycylamide, D-lysyl(N-epsilon-acetyl)amide, a group represented by the formula —NH—(CH2)n—CHR1R2;
- and a group represented by the formula —NHR , wherein n is an integer from 0 to 8;
- R1 is selected from the group consisting of hydrogen, alkyl, cycloalkenyl, and cycloalkyl;
- R2 is selected from the group consisting of hydrogen, alkoxy, alkyl, aryl, cycloalkenyl, cycloalkyl, heterocycle, and hydroxyl, with the proviso that when n is 0, R2 is other than alkoxy or hydroxyl;
- and R3 is selected from the group consisting of hydrogen, cycloalkenyl, cycloalkyl, and hydroxyl.
12 more elements
Dependencies are inferred from the claim text.